Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
AIMS: Schizophrenia has the highest median societal cost per patient of all mental disorders. This review summarizes the different costs/cost drivers (cost components) associated with schizophrenia in 10 countries, including all cost types and stakeholder perspectives, and highlights aspects of disease associated with greatest costs. MATERIALS AND METHODS: Targeted literature review based on a search of published research from 2006 to 2021 in the United States (US), United Kingdom (UK), France, Germany, Italy, Spain, Canada, Japan, Brazil, and China. RESULTS: Sixty-four published articles (primary studies and literature reviews) were included. Comprehensive data were available on costs in schizophrenia overall, with very limited data for individual countries except the US. Most data is related to direct and not indirect costs, with extremely scarce data for several key cost components (adverse events, suicide, long-term care). Total schizophrenia-related per person per year (PPPY) costs were $2,004-94,229, with considerable variability among countries. Indirect costs were the main cost driver (50-90% of all costs), ranging from $1,852 to $62,431 PPPY. However, indirect costs are not collected systematically or incorporated in health technology assessments. Total schizophrenia-related PPPY direct costs were $4,394-31,798, with inpatient cost as the main cost driver (∼20-99% of direct costs). Intangible costs were not reported. Despite limited evidence, total schizophrenia-related costs were higher in patients with than without negative symptoms, largely due to increased costs of medication and medical visits. LIMITATIONS: As this was not a systematic review, prioritization of studies may have resulted in exclusion of potentially relevant data. All costs were converted to USD but not corrected for inflation or subjected to a gross domestic product deflator. CONCLUSIONS: Direct costs are most commonly reported in schizophrenia. The substantial underreporting of indirect and intangible costs undervalues the true economic burden of schizophrenia from a payer, patient, and societal perspective.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In ophthalmology, as in other disease areas, the research reflects three main categories of costs, including direct (medical and non-medical), indirect and intangible costs [22, 27–29].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [29]
In the citing paper
“Experts have recognized the importance of adopting a standardized approach when quantifying costs, which ensures adequate comparisons across studies, especially in the case of systematic reviews where the fullness of incurred costs (including direct, indirect and intangible) pertaining to a particular disease area need to be reflected [22, 28, 29].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [29]
Citations
Cites
Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby058 · Cited by 1,647
McCutcheon, R. A., Reis Marques, T., & Howes, O. D. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.3360 · Cited by 1,481
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, M. F., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.177901 · Cited by 912
The Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614
Negative symptoms of schizophrenia: new developments and unanswered research questions
Galderisi, S., Mucci, A., Buchanan, R. W., & Arango, C. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30050-6 · Cited by 555
The Global Costs of Schizophrenia
Knapp, M., Mangalore, R., & Simon, J. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007078 · Cited by 536
The Economic Burden of Schizophrenia in the United States in 2013
Cloutier, M., Sanon Aigbogun, M., Guerin, A., Nitulescu, R., Ramanakumar, A. V., Kamat, S. A., DeLucia, M., Duffy, R., Legacy, S. N., Henderson, C., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10278 · Cited by 477
Rabinowitz, J., Levine, S. Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C. G., & Kapur, S. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.01.015 · Cited by 366
Cost of schizophrenia in England.
Mangalore, R., & Knapp, M. R. J. (2007) · PubMed · Cited by 322
Research works printed but not linked: 3
- Steinert T, Krueger M, Gebhardt RP. Costs of treatment and outcome measures in schizophrenia. Eur J Psychol Assess. 1999;13:209–214.
- Wilson LS, Gitlin M, Lightwood J. Schizophrenia costs for newly diagnosed versus previously diagnosed patients. Am J Pharm Benefits. 2011;3(2):107–115.
- Esposti LD, Sangiorgi D, Ferrannini L, et al. Cost-consequences analysis of switching from oral antipsychotics to long-acting risperidone in the treatment of schizophrenia (provisional abstract). J Psychopathol. 2012;18(2):170–176.
Cited by
Association Between Unemployment and Mental Disorders: A Narrative Update of the Literature
Franke, A. G., Schmidt, P., & Neumann, S. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21121698 · Cited by 36
Cohen, A., Naslund, J. A., Lane, E., Bhan, A., Rozatkar, A. R., Mehta, U. M., Vaidyam, A. N., Byun, A. J. S., Barnett, I., & Torous, J. B. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13712 · Cited by 32
The hidden costs of informal caregiving: a concept analysis
Gu, J., Sun, X., Shi, Y., Wang, S., Wang, P., Liu, Y., Liu, Y., & Wang, P. (2024) · BMC Nursing · doi:10.1186/s12912-024-02293-1 · Cited by 30
Digital Phenotyping in Adults with Schizophrenia: A Narrative Review
Lane, E., D’Arcey, J., Kidd, S. A., Onyeaka, H., Alon, N., Joshi, D., & Torous, J. B. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01467-z · Cited by 28
Correll, C. U., Xiang, P., Sarikonda, K., Bhagvandas, N., & Gitlin, M. D. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24r15316 · Cited by 25
Metadata
- Authors
- Kotzeva, A., Mittal, D., Desai, S., Judge, D., & Samanta, K.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Bridge Medical Consulting Ltd, Richmond, UK
- Roche (United Kingdom) (GB)
- Corresponding author
- Kotzeva, Anna
- Venue
- Journal of Medical Economics
- Publisher
- Informa UK Limited
- Published
- 2022-12-25
- Volume
- 26
- Issue
- 1
- Pages
- 70-83
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W4311206227
- Cited by
- 57
- References
- 76
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 16 · 2023: 7
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Journal of Medical Economics (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- schizophrenia, economic burden, social costs, indirect costs, direct costs, hospital costs, negative symptoms, cost drivers, suicide, long-term care, adverse events, intangible costs, cross-national comparison
- MeSH terms
- China, Humans, Long-Term Care, Schizophrenia, Socioeconomic Factors, United States, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. https://app.cochat.ai/papers/10.1080/13696998.2022.2157596
- The paper
- Kotzeva, A., Mittal, D., Desai, S., Judge, D., & Samanta, K. (2023). Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. Journal of Medical Economics. https://doi.org/10.1080/13696998.2022.2157596
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.